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Endothelin-1 and angiotensin II modulate rate and
contraction amplitude in a subpopulation of mouse
embryonic stem cell-derived
cardiomyocyte-containing bodies
E.L. Lagerqvist, B.A. Finnin, C.W. Pouton, J.M. Haynes⁎Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus),
Melbourne, Australia
Received 8 March 2010; received in revised form 8 September 2010; accepted 10 September 2010Abstract Embryonic stem cell-derived cardiomyocytes (ESC-CMs) have applications in understanding cardiac disease
pathophysiology, pharmacology, and toxicology. Comprehensive characterization of their basic physiological and pharmacological
properties is critical in determining the suitability of ESC-CMs as models of cardiac activity. In this study we use video microscopy
and quantitative PCR to investigate the responses of mouse ESC-CMs to adrenoceptor, muscarinic, angiotensin II (Ang II), and
endothelin-1 (ET-1) receptor activation. Isoprenaline (10 nM–10 μM) increased beating rate and contraction amplitude in all
beating bodies (BBs), whereas carbachol (up to 1 μM) and the If channel blocker ZD-7288 (10 μM) decreased contraction frequency.
ET-1 (0.01–100 nM) reduced contraction amplitude in all BBs and increased contraction frequency in 50% of BBs; these effects were
blocked by the ETA receptor antagonist BQ123 (250 nM). Ang II (0.01 nM–1 μM) increased both contraction amplitude (all BBs) and
frequency (in 50% of BBs), effects blocked, respectively, by losartan (100 nM) and PD123,319 (200 nM). These results indicate the
presence of functional ETA and both AT1 and AT2 receptors in murine ESC-CMs, but their expression and or activity appears to be
evident only in a limited set of BBs.
© 2010 Elsevier B.V. All rights reserved.Introduction
Embryonic stem cells (ESCs) are undifferentiated cells that
can differentiate into all adult cell types. Following the
initial isolation of mouse ESCs (mESCs) in 1981 (Evans and
Kaufman, 1981), methods for the in vitro differentiation of
mESC-derived cardiomyocytes (mESC-CMs) have been well⁎ Corresponding author. 381 Royal Parade, Parkville, Victoria
3052, Australia. Fax: +61 3 9903 9143.
E-mail address: john.haynes@pharm.monash.edu.au
(J.M. Haynes).
1873-5061/$ – see front matter © 2010 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2010.09.001established. The most common protocol involves the
cultivation of three-dimensional aggregates called embryoid
bodies (EBs) which, when plated, give rise to spontaneously
beating cardiomyocytes within a mixed cell aggregate
(Wobus et al., 2002).
Expression profiling of the transcription factors involvedwith
heart development in vivo, as well as electrophysiological and
morphological studies, has shown that ESC-CMs exhibit proper-
ties indicative of early myocardial development (Boheler et al.,
2002; Fijnvandraat et al., 2003). Nevertheless, some studies
have reported the successful engraftment of these developing
ESC-CMs to injured myocardium (Laflamme et al., 2007; Klug
et al., 1996; Hodgson et al., 2004). In addition, these ESC-CMs
can potentially serve as readily available and functional in vitro.
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24 E.L. Lagerqvist et al.cardiac models for basic research and in drug discovery and
development programs (Pouton and Haynes, 2007). Consider-
ation for the use of ESC-CMs in replacement therapies and as
models of cardiac activity must be linked to a comprehensive
characterization of their basic physiological and pharmacolog-
ical properties, an area not well established.
Most studies investigating cardiomyocyte differentiation
from ESCs have used isoprenaline and carbachol as the
“standard” agonists to confirm that the physiological or
electrophysiological properties of the derived cardiomyocytes
resemble native tissue (Banach et al., 2003; He et al., 2003; Fu
et al., 2006). However, little is known about ESC-CM respon-
siveness to other endogenous neurotransmitters, peptides, and
cardioactive drugs. Some work on the effect of angiotensin II
(Ang II) and endothelin-1 (ET-1) has been carried out on single,
isolatedmESC-CMs (Kapur andBanach, 2007), aswell as in paced
human ESC (hESC)-CMs (Sedan et al., 2008). However, the
specific receptor(s) mediating these responses, and the effects
of these bioactive peptides on both the contraction frequency
and the amplitude of spontaneously contracting mESC-CMs, is
unknown. In this study, we investigate the responsiveness of
mESC-CMs to two physiologically relevant peptides, Ang II and
ET-1, and compare their effects with those of standard
agonists such as isoprenaline and carbachol. We report that
the acute effects of these peptides on ESC-CM contractility are
mediated through ETA, AT1, and AT2 receptors, and also that,
in contrast to the effects of other agonists, the chronotropic
effects of these peptides are only evident in a limited subset of
beating ESC-CM-containing bodies.EDS LDS 
0
EDS LDS
0
Figure 1 qPCR of Nkx2.5-EGFP-positive cells reveals no
differential expression of AT1, ETA, or ETB receptors between
EDS (seven day) and LDS (18 day) cardiomyocytes. The AT2
receptor, however, is only expressed in LDS cardiomyocytes. Tbp
indicates the TATA binding protein housekeeping gene control.Results
Quantitative PCR
Nkx2.5-EGFP-positive cells were sorted by FACS at Days 8 and
18 of differentiation for qPCR analysis of cardiac-specific
gene expression. Whereas there were no significant differ-
ences in the expression levels of the AT1a, ETA, and the ETB
receptor between cardiomyocytes differentiated over seven
(EDS) and 18 (LDS) days, the AT2 receptor was only expressed
in LDS cardiomyocytes (Fig. 1).Effects of isoprenaline (ISO) and carbachol
All LDS beating bodies (BBs) responded to ISO (10 nM–10 μM)
with an increase in both contraction amplitude and frequency
(Figs. 2A and B, Pb0.001, one-way ANOVA, post hoc Dunnett's,
n=8), and to carbachol (100 nM–1 μM) with a decrease in both
contraction amplitude and frequency (Fig. 2C).Effects of ZD-7288, ryanodine, and thapsigargin
The If blocker ZD-7288 over a period of 20 min decreased
contraction frequency in every LDS BB (Fig. 2D). Ryanodine
(10 μM) and thapsigargin (0.5 μM) significantly decreased both
contraction amplitude and frequency in every BB (Fig. 3;
Pb0.01, Student's t test, n=4–5).Effects of ET-1
All EDS BBs responded to ET-1 (10 nM) with an increase in
contraction amplitude, whereas this response was reversed
in LDS BBs (0.01–100 nM) (Pb0.05, one-way ANOVA, post hoc
Dunnett's, n=2–8, Figs. 4A and B). Only 50% of the BBs
responded to ET-1 with an increase in contraction frequency
in both EDS and LDS BBs (Fig. 4C, EDS data not shown), with
LDS responding bodies showing a concentration-dependent
increase in the number of responders (EC50 2.14±0.41 nM;
Fig. 4D). As the maximum effect of ET-1 on contraction
amplitude, frequency, and number of responding BBs was
observed following the addition of 10 nM ET-1, this concen-
tration was used for subsequent antagonist studies.
The decrease in contraction amplitude mediated by 10 nM
ET-1 was abolished by the ETA receptor antagonist BQ123
(250 nM) and incubation with pertussis toxin (PTX; 1 μg mL-1;
Pb0.05, one-way ANOVA, post hoc Dunnett's, n=4–5). The ETB
receptor antagonist BQ3020 (10 nM), the IP3 receptor inhibitor
2-aminoethoxydiphenyl borate (2-APB; 2 μM), and the protein
kinase C (PKC) inhibitor GF109203x (1 μM) had no effect on the
ET-1-mediated decrease in contraction amplitude (Fig. 5A).
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Figure 2 Mean responses to the addition of ISO (10 nM–3 μM) which increased both (A) contraction amplitude and (B) contraction
frequency (Pb0.001, one-way ANOVA, post hoc Dunnett's test, n=8). (C) Carbachol (100 nM–1 μM) decreased both contraction frequency
and amplitude (Pb0.001, one-way ANOVA, post hoc Dunnett’s test, n=8). (D) If blocker ZD7288 significantly decreased spontaneous beating
rate (10 µM, Pb0.001, Student’s t test, n=7).
25Subpopulation of mouse embryonic stem cell-derived cardiomyocyte-containing bodiesThe ET-1-mediated increase in contraction frequency was
blocked by BQ123 (250 nM) and GF109203x (1 μM; Pb0.05, one-
way ANOVA, post hoc Dunnett's; n=5). Incubation of the mESC-
CMs with BQ3020 (10 nM), 2-APB (2 μM), or PTX (1 μg mL-1) had
no effect on the contraction frequency response to ET-1
(Fig. 5B). Addition of the PKC activator phorbol 12,13-diacetate
(PDA) increased contraction frequency in every BB (by 77±13%
at 10 μM, respectively, Pb0.05, one-way ANOVA, post hoc
Dunnett's, n=5–6; Fig. 5C).Effects of Ang II
Ang II (10 pM–1 μM) increased contraction amplitude in LDS
BBs, maximally at 100 nM (Pb0.05, one-way ANOVA, post hoc
Dunnett's, n=2–8, Fig. 6A), but had no effect in EDS BBs
(data not shown). Similar to ET-1, both EDS and LDS BBs
demonstrated a concentration-dependent increase in the
contraction frequency responders to Ang II, up to 50% of BBs
(EC50 0.49±0.26 nM; Figs. 6B and C).This increase in contraction amplitude was reduced by the
selective AT1 antagonist losartan (200 nM) and by 2-APB (2 μM;
Pb0.05, one-way ANOVA, post hoc Dunnett's, n=4–6), but the
AT2 receptor antagonist PD123, 319 (200 nM), PTX (1 μg mL-1),
and GF109203x (1 μM) did not have any effect (Fig. 7A).
The Ang II (100 nM)-mediated increase in contraction
frequency was reduced by PD123,319 (200 nM), GF109203x
(1 μM), and 2-APB (2 μM; Pb0.01, one-way ANOVA, post hoc
Dunnett's, n=3–6). Incubation with losartan (200 nM) or PTX
(1 μg mL-1) had no effect on the frequency response to Ang II
(Fig. 7B).Discussion
In this study, we have successfully differentiated mESCs into
cardiomyocyte-containing BBs and measured their responsive-
ness to several agonists vital for the physiological functioning of
cardiomyocytes in vivo. One of the parameters measured was
changes in contraction amplitude; the second parameter of
interestwas contraction frequency. The cessation of contractile
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Figure 3 Investigation of sarcoplasmic reticular function. 0.5 μM thapsigargin and 10 μM ryanodine significantly decrease both
(A and C) contraction frequency and (B and D) contraction amplitude, respectively.
26 E.L. Lagerqvist et al.activity in these ESC-BBs in the presence of ZD7288 indicates a
significant contribution of If to spontaneous contraction
frequency, a finding consistent with the presence of pacemaker
cells driving either, or both, atrial or ventricular cardiomyocyte
contractions in these cardiac bodies (Boheler et al., 2005;
Maltsev et al., 1993). Therefore, changes in contraction
frequency can be interpreted as effects mediated via changes
in pacemaker cell activity (Kang et al., 2007). We have shown
positive and negative effects on both contraction amplitude and
frequency in response to isoprenaline and carbachol, respec-
tively, findings consistent with observations of β-adrenoceptor
and muscarinic effects in the native mouse heart and previous
studies in mESC-CMs (Lee et al., 2008; Ali et al., 2004; Kitazawa
et al., 2009).
ET-1 serves as an autocrine/paracrine factor produced
and released by both cardiomyocytes (Suzuki et al., 1993)
and endothelial cells (Brutsaert, 2003). This potent peptide
mediates its effects through two G-protein-coupled recep-
tors: ETA and ETB. Both ET receptor subtypes have been
localized to the atrial and ventricular myocardium, the
atrioventricular conducting system, and endocardial cells
(Molenaar et al., 1993; Pönicke et al., 1998; Pieske et al.,
1999; Del Ry et al., 2001; Fareh et al., 1996). Activation of
ETA and ETB receptors may initiate signaling through several
pathways. Their effects are commonlymediated through Gq/11
activation; however, they have been reported to be coupled
through Gs or Gi in particular cell types and species (Ono et al.,
1998; Aramori and Nakanishi, 1992). In general, largermammals tend to respond to ET-1 with increased contractility
(Endoh, 2006); however, during development the mouse heart
response to ET-1 changes from positive to negative effects on
cell shortening (Sekine et al., 1999; Izumi et al., 2000;
Nagasaka et al., 2003; Namekata et al., 2008; Sakurai et al.,
2002). The reversal of the ET-1-mediated increase in
contraction amplitude in our EDS BBs to a decrease in
contraction amplitude in LDS BBs provides strong support for
the functional maturation of mESC-CMs 18 days after the
initiation of differentiation.
LDS BBs were found to respond to ET-1 stimulation with a
decrease in cell shortening. Furthermore, our findings that
BQ123, but not BQ3020, blocked the negative shortening
response to ET-1 are consistent with those of Izumi and co-
workers (Izumi et al., 2000) and indicate an ETA receptor-
mediated effect. Curiously, ET-1, in the presence of the ETA
receptor antagonist BQ123, produced an increase in cell
shortening. Furthermore, ET-1 concentrations above 10 nM
show a reduced negative response. These findings may indicate
that ET-1 acts at both ETA and ETB receptors to elicit negative
and positive changes in cell shortening, with the ETA receptor
effect predominating at low concentrations. Physiological
antagonism between the ETA and the ETB receptors has been
observed in several studies (for a review, see Brunner et al.
(Brunner et al., 2006). Thus, we conclude that ETA mediates a
decrease in cell shortening via activation of Gi/o proteins, but
we cannot rule out an ETB-mediated positive effect in these
cells.
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Figure 4 Mean responses to the addition of ET-1. (A) LDS BBs respond to ET-1 stimulation with a decrease in contraction amplitude,
maximal at 10 nM (Pb0.05 Student's t test, n=4–8). (B) However, EDS BBs respond to 10 nM ET-1 with an increase in contraction
amplitude. (C) ET-1 increased contraction frequency in LDS BBs, again maximal at 10 nM ET-1 (Pb0.05, Student's t test, n=2–8).
(C) However, only a maximum of 50% of the cultures responded to ET-1 (up to 100 nM) with an increase in contraction frequency.
27Subpopulation of mouse embryonic stem cell-derived cardiomyocyte-containing bodiesIn contrast to previous studies that attributed the ET-1-
mediated cell shortening response to PKC activation (Izumi
et al., 2000; Namekata et al., 2008), we found that PTX
blocked the ET-1-mediated decrease, implicating Gi/o
protein coupling, rather than Gq/11. Gi/o coupling of ET
receptors is common in other species (Ono et al., 1998; Liu
et al., 2003; Kim, 1991). However, even though studies have
demonstrated ET receptor coupling to both Gq/11 and Gi/o in
adult mouse heart (Jiang et al., 1996; Hilal-Dandan et al.,
1992; Hilal-Dandan et al., 2000), it has not been associated
with negative cell shortening effects of ET-1 in the mouse.
The renin angiotensin system plays a central role in the
regulation of cardiac function. Ang II is the system's main
effector and is known to mediate a wide range of physiological
and pathophysiological effects following acute and chronic
stimulation (Mehta and Griendling, 2007). In the heart, Ang II
mediates both inotropic and chronotropic effects via two G-
protein-coupled receptor types, AT1 and AT2. These two
receptors have similar affinities for Ang II, and are currently
distinguished by affinities for antagonists such as losartan (AT1)
and PD123,319 (AT2). The AT1 receptor is thought to be
the prime mediator of Ang II effects and has been linked
to several signaling cascades, most commonly Gq/11 couplingwith subsequent PLC and PKC activation (De Gasparo et al.,
2000). The Ang II-mediated effect on the contractility of the
mouse heart varies depending on the tissue being examined
(Sakurai et al., 2002; Nishimaru et al., 2003). In this study, Ang II
induced a slight increase in contraction amplitude, a finding
consistent with effects seen in mouse atria (Nishimaru et al.,
2003). This effect was blocked by losartan and 2-APB, but not
by PTX, PD123,319, or GF109203x, and is consistent with a
previous studyofAng II effects in humanESC-CMs acting viaGq/11
proteins with subsequent PLC and IP3 production (Sedan et al.,
2008).
One of the most interesting aspects of this study is that the
PKC-mediated positive chronotropic response to both ET-1 and
to Ang II was only observed in a maximum of 50% of BBs. To
determinewhether thiswas due to the lack of developed second
messenger signaling pathways in the nonresponding population,
the effect of the PKC activator PDA was investigated. However,
all BBs were found to respond to direct PKC activation,
indicating that the second messenger pathway is intact in
every culture even though half of the BBs are unresponsive to
peptide addition. Previous studies using human ESC-CMs have
also reported the presenceof nonresponding cultures,which has
been attributed to the lack of a functional sarcoplasmic
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igure 5 Mean responses to the addition of ET-1 in the
resence of antagonists. (A) Both BQ123 (250 nM) and PTX (1 μg
L-1) inhibited the ET-1 (10 nM) decrease in contraction ampli-
ude (Pb0.05, one-way ANOVA, post hoc Dunnett's, n=4–5).
) BQ123 (250 nM) and GF109203x (1 μM) blocked the ET-1-
ediated increase in contraction frequency (Pb0.05, one-way
NOVA, post hoc Dunnett's, n=5). (C) The PKC activator PDA
ignificantly increased contraction frequency (Pb0.05, one-way
NOVA, post hoc Dunnett's, n=5–6).
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Figure 6 Mean responses to the addition of Ang II. (A) Ang II
increases contraction amplitude at 100 nM (Pb0.05, Student's
t test, n=4–8) (B) with a concentration-dependent increase in
contraction frequency, maximal at 100 nM (Pb0.05, Student's
t test, n=2–8). (C) A maximum of 50% of the cultures responded
to Ang II (up to 1 μM) with an increase in contraction frequency.
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(Sedan et al., 2008). However, in our study, this observation
appears to be specific to peptide effects since (1) all BBs
responded to thapsigargin and ryanodine, indicating the
presence of a functional sarcoplasmic reticulum, (2) all BBs
responded to isoprenaline and carbachol addition, and (3)
beating in all bodies was reduced by the If channel blocker.
Furthermore, no correlation was found between a nonrespond-
ing BB and other observable properties, such as the initial
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Figure 7 Mean responses to theaddition of Ang II in thepresence
of antagonists. (A) Losartan (200 nM) and 2-APB (2 μM) abolished
theAng II (100 nM) increase in contraction amplitude (Pb0.05, one-
way ANOVA, post hoc Dunnett's, n=4–6) (B) PD123,319 (200 nM),
GF109203x (1 μM), and 2-APB (2 μM) inhibited the Ang II (100 nM)
increase in contraction frequency (Pb0.05, one-way ANOVA, post
hoc Dunnett's, n=3–6).
29Subpopulation of mouse embryonic stem cell-derived cardiomyocyte-containing bodiesbeating frequency or individual batches of differentiated cells.
A recent study in mESC-CMs identified two separate pacemaker
populations based on hyperpolarization-activated cyclic nucle-
otide gated channel expression, activation kinetics, and cAMP
sensitivity (Barbuti et al., 2009). We think it possible that an
analogous situation exists in our cultures where approximately
one-half of our beating body contains pacemakers insensitive to
peptide effects. This is consistent with the idea of “functional
inhomogeneity” resulting froma significant variation in receptor
densities within the sinus node (Opthof, 2007). As investigating
the function of individual pacemaker cells within an EB is near
impossible, studies at the single cell level are ongoing to
determine differences in receptor expression and signaling
pathway activation within the pacemaker population.
Of the population that does respond to the peptides with
changes in chronotropy ET-1, acting via ETA receptors, elicited aPKC-dependent, pertussis toxin- and 2-APB-insensitive positive
chronotropic response. This finding is broadly consistent with a
previous study in mESC-CMs (Kapur and Banach, 2007).
However, in contrast to our findings, Kapur and Banach (Kapur
andBanach, 2007) showed that thepositive chronotropic effects
were mediated by phospholipase C (PLC) with subsequent IP3
receptor activation. In this study the IP3 receptor antagonist 2-
APB was without effect, indicating either that we have not used
enough 2-APB or that themajority of ETA signaling in these cells
is mediated via PKC effects. The former hypothesis is unlikely
since the same concentration of 2-APB reduced the effects of
Ang II, leaving us to conclude that, in these cardiomyocytes, the
ET-1 effect is largely attributable to the action of PKC.
In this study the AT2 receptor antagonist PD312,319
blocked the GF109203x-, 2-APB-sensitive Ang II-mediated
increase in contraction frequency. Previous studies have
demonstrated an AT2 receptor (PKC-dependent)-mediated
effect on contractility (Allen et al., 1988; Kohout and Rogers,
1995); however, the AT2 receptor is normally highly
expressed in the fetus and dramatically reduced in the
adult; where it is predominantly located on the vascular
endothelium (Grady et al., 1991; Wang et al., 1998).
In these ESC-CMs, onset of AT2 receptor expression does not
occur until at least Day 8 postdifferentiation and is definitively
present in LDS CMs. Together with its demonstrated effect on
contractile activity, this could imply a less developed Ang II
system compared to ET-1, an observation consistentwithwhat
is known about Ang II signaling in rodents (Kang et al., 2007).
Current studies are investigating the developmental progres-
sion of Ang II signaling in these ESC-CMs in more detail.
Conclusion
Use of ESC-CMs for cell-based therapy and in vitro applications
during drug discovery necessitates comprehensive character-
ization of their functional activity. In this study, we have used
video microscopy to (i) compare the modulation of cardiac
contractile activity by various agonists vital for the physiolog-
ical function of cardiomyocyte in vivo, (ii) investigate which
second messenger systems the peptide agonists activate to
produce their responses, and (iii) used these data to establish
just how like normal adult heart tissue these ESC-CMs are.
Wehavedemonstrated that thesemESC-CMcultures respond
to stimulation through functional adrenoceptor, muscarinic,
Ang II, and ET-1 receptors, and possess intact Gq/ll and Gi/o
signaling cascades in amanner comparable to previous studies in
the native mouse myocardium. However, even though we
demonstrate the progressive maturation of these CMs by the
reversal of their cell shortening response to ET-1 between EDS
and LDS BBs, and that all BBs have functional sarcoplasmic
reticulum, the pacemaker population within the BBs can be
divided on the incidence of their response to Ang II and ET-1.
Further investigations are required to better characterize the
pacemaker populations in these differentiated cultures.
Materials and methods
ESC propagation
The mouse ESC lines E14Tg2a (ATCC, catalogue number CRL-
1821) and Nkx2.5-EGFP line (a kind gift from Dr. Sean Wu)
Gene Primer sequence Product size
(bp)
TATA binding
protein
CTGCTGTTGGTGATTGTTGG 100
AACTGGCTTGTGTGGGAAAG
AT1a receptor CCAACTCAACCCAGAAAAGC 147
CCACCACAAAGATGATGCTG
AT2 receptor GGAGCTCGGAACTGAAAGC 131
CTGCAGCAACTCCAAATTCTT
ETA receptor ATCGGGATCCCCTTGATTAC 140
TTGAGCATGCAGGTCCTATG
ETB receptor GCCTGAAGTTCAAAGCCAAC 94
AGATTCGGCGAGTGTTCTTG
30 E.L. Lagerqvist et al.were propagated in a culture medium consisting of GlutaMAX
Dulbecco's minimum essential medium (DMEM, pH 7.4)
supplemented with 0.1 mM MEM nonessential amino acids
solution, 10% fetal calf serum (FCS), 0.1 mM 2-mercap-
toethanol, 103 U mL-1 murine recombinant leukemia inhib-
itory factor (Chemicon, Australia). Cultures were incubated
at 37 °C, 5% CO2 in a humidified environment.
ESC-CM differentiation
Cardiomyocyte differentiation was induced by the hanging
drop method (Boheler et al., 2002). Briefly, embryoid bodies
were formed in hanging drops of differentiation medium
(propagation medium supplemented with 20% FCS, 10,000 U
mL-1 penicillin and 10,000 μg mL-1 streptomycin) for 5 days.
EBs were subsequently plated on gelatin-coated wells for the
remainder of the differentiation period. Contractility studies
were used to investigate cardiomyocyte responsiveness at
both early and late developmental stages, i.e., Days 7 (EDS)
and 18 (LDS) post differentiation. Fu et al. have shown that
by this LDS, mESC-CMs demonstrate a functional sarcoplas-
mic reticulum (SR) with ryanodine receptor-mediated SR
calcium release, and pharmacological maturity in response
to β-adrenergic stimulation (Fu et al., 2006).
Quantitative real-time PCR
Nkx2.5-EGFP-positive cells were collected on Days 8 and 18
postdifferentiation by fluorescence-activated cell sorting.
Total RNA was extracted using the RNeasy Micro kit
(Qiagen, Australia), treated with DNase I to remove the
contaminating genomic DNA, before reverse transcription
into cDNA by Transcriptor Reverse Transcriptase (Roche
Applied Science, Australia) and random primers according
to the manufacturer's specifications. Quantitative real-
time PCR analysis was carried out in triplicate for each
sample and each gene using the Rotor Gene 3000 (Corbett
Robotics, Australia). For PCR amplification, cDNAs were
amplified using Roche SYBR Green PCR Master Mix (Roche
Applied Science, Australia) and 1 μM of each primer pair.
Amplification was carried out starting with 10 min template
denaturation/hot start step at 95 °C, followed by 35 cycles
(95 °C for 15 s, 59 °C for 20 s, and 72 °C for 20 s). Relative
gene expression values were obtained by normalizing CT
(threshold cycle) values of the target genes in comparison
with CT values of the housekeeping gene (TATA binding
protein) using the ΔΔCT method. Gene-specific primer
sequences are provided in Table 1.
Experimental methodology
On the day of use, the E14Tg2a EB outgrowths were washed
twice and superfused with a physiological salt solution (PSS)
buffer consisting of (in mM) NaCl 140, KCl 6, CaCl2 2, MgCl2 1,
HEPES 20, and glucose 10 (pH 7.4, 37 °C), supplemented with
1.4% (w/v) BSA. A single beating region within an EB
outgrowth was selected and viewed through a Basler
(Model A602f) camera coupled to a Nikon Eclipse TS100
inverted microscope with Hoffman modulation contrast
optics. The Quick Caliper program (SDR Clinical Technolo-
gies, Australia) enabled image acquisition at a rate of 50frames per second. Ten-second video captures were taken ofTable 1 Qua titative PCR primer sequencesa beating cardiac region pre- and postagonist addition, in the
absence and presence of antagonists.
Following a 10min equilibration period, a 10s capture was
taken of the selected beating region to quantify basal activity.
Subsequently, Ang II (0.01–1 μM), ET-1 (0.01–100 nM), isopren-
aline (10 nM–10 μM), carbachol (100 nM–1 μM), ryanodine
(10 μM), thapsigargin (0.5 μM), the If blocker ZD-7288 (10 μM),
or the protein kinase C activator phorbol 12,13-diacetate
(10 nM–10 μM) was added to the well and 10s image captures
were taken at various time points up to 20min postagonist or
vehicle addition.
For antagonist and inhibitor studies, BBs were superfused
with the AT1 and AT2 receptor antagonists, losartan (200 nM)
and PD123, 319 (200 nM), or the ETA and ETB receptor
antagonists, BQ123 (250 nM) or BQ3020 (10 nM) for 10 min
prior to the addition of agonists. In some experiments, the
BBs were superfused with the inositol trisphosphate (IP3)
receptor antagonist 2-aminoethoxydiphenyl borate (2 μM,
which may also inhibit store-operated calcium channels at
higher concentrations (Choi et al., 2010), or the PKC
inhibitor GF109203x for 10 min prior to agonist addition.
Pertussis toxin (1 μg mL-1) was added to the differentiation
medium at least 3 h prior to the superfusion experiments.
Images were captured as described above.
Data analysis
The video captures were analyzed using Metamorph Imaging
System (Molecular Devices Ltd, USA). An intensity threshold
was imposed on each frame of a 10s image capture. The
Metamorph software was then used to track object move-
ment through the 10s image capture. The contraction
amplitude (measured in pixels) was tracked at different
time points plotted against time (Fig. 8A). The number of
peaks within the 10s capture was converted to beats per
minute to represent the cardiomyocyte contraction frequen-
cy. The average contraction amplitude and frequency
responses to agonist, in the absence or presence of
antagonist(s), were reported as a percentage of the
responses prior to agonist addition (i.e., under basal
conditions). Figs. 8B and C show representative traces of
LDS EBs responses prior to and following the addition of ET-1
(10 nM) or Ang II (100 nM), respectively.
Figure 8 (A) Capture analysis using Metamorph. (a) A beating region within the well was viewed through a camera coupled to a
Nikon Eclipse TS100 inverted microscope with Hoffman modulation contrast optics. Ten-second captures of a beating cardiac region
were recorded, and subsequently analyzed using the Metamorph program. (b) An intensity threshold is set using the phasecontrast
image. (c) Several particles are selected and monitored within the area of interest. (d) The particle showing the greatest displacement
from its point of origin is selected and tracked at the remaining time points. (e) A graph of displacement from origin (in pixels) is
generated over the 10s capture period. Two representative 10s traces before and after the addition of (B) ET-1 (10 nM) showing an
increase in the number of peaks within the 10s trace (i.e., rate) and a decrease in contraction amplitude. (C) In response to Ang II (100
nM), the number of peaks as well as contraction amplitude (in pixels) increases.
31Subpopulation of mouse embryonic stem cell-derived cardiomyocyte-containing bodiesStatistical analysis
The maximum responses observed for contraction ampli-
tude and frequency were reported. Curiously, only a
proportion of the mESC-CMs responded to Ang II or ET-1with a change in contraction frequency. Responding and
nonresponding BBs were identified using a repeated-
measures one-way ANOVA test of the time interval between
beats at each 10s capture. Only responding BB effects were
reported for analysis of peptide effects on contraction
32 E.L. Lagerqvist et al.frequency. None of the vehicles, Ang II or ET-1 receptor
antagonists, or 2-APB, PTX, and GF109203x had any
effect on the basal spontaneous activity of our cultures
(n=4–7, data not shown). Differences between means
were tested using Student's t test and one-way ANOVA
(post hoc Dunnett's). Values of Pb0.05 were considered
statistically significant (n=3–8 responding bodies from 4
to 8 observations).
Drugs and chemicals
Ang II, ET-1, BQ123, BQ 3020, carbachol, ryanodine, PD 123,
319, and losartan were reconstituted in PSS buffer. PDA,
thapsigargin, and GF109203x were dissolved in DMSO. 2-APB
was dissolved in methanol. The PTX vehicle contained 50%
glycerol, 0.5 M NaCl, 50 mM tris, 10 mM glycine (pH 7.5). The
final concentration of DMSO or methanol did not exceed
0.01% of the bath volume. PDA and ryanodine were
purchased from Calbiochem-Novabiochem (Australia) and
thapsigargin was purchased from LC laboratories (USA). All
other drugs and chemicals were purchased from Sigma-
Aldrich (Australia).Acknowledgments
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